Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.56 |
| ▸ | NPY4R | P50391 | 3/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 13/20 | 0.55 |
| ▸ | MC4R | P32245 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31193767 | 0.96 | NPY4R (0.60) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL31193750 | 0.94 | NPY4R (0.58) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL30635329 | 0.94 | ECE1 (0.52) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL17827357 | 0.94 | ECE1 (0.52) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL28175487 | 0.94 | ECE1 (0.52) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL29641173 | 0.94 | GHSR (0.60) | — | |
| SCHEMBL29483770 | 0.94 | GHSR (0.60) | — | |
| SCHEMBL29483769 | 0.94 | GHSR (0.60) | — | |
| SCHEMBL22117388 | 0.94 | KISS1R (0.61) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL22117389 | 0.94 | KISS1R (0.61) | NPY1RNPY2RNPY4RKISS1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205164-A1 | FPR2 AGONIST CONTAINING OUTER MEMBRANE VESICLES DERIVED FROM LACTIC ACID BACTERIUM | ASAHI GROUP HOLDINGS, LTD. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4548780-A1 | FPR2 AGONIST CONTAINING OUTER MEMBRANE VESICLES DERIVED FROM LACTIC ACID BACTERIUM | Asahi Group Holdings, Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12065485-B2 | Treatment of staphylococcal disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2023229034-A1 | FPR2 AGONIST CONTAINING OUTER MEMBRANE VESICLES DERIVED FROM LACTIC ACID BACTERIUM | アサヒグループホールディングス株式会社 | 2023-11-30 | — | — | WO | disclosed |
| US-20220048979-A1 | TREATMENT OF STAPHYLOCOCCAL DISORDERS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2022-02-17 | — | — | US | disclosed |